Jacobs, Tom G, Marzolini, Catia, Back, David J and Burger, David M
(2022)
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77 (3).
pp. 568-573.
Abstract
Global use of dexamethasone in COVID-19 patients has revealed a poor understanding of the drug-drug interaction (DDI) potential of dexamethasone, particularly with antiretroviral agents (ARVs). Dexamethasone is both a substrate and a dose-dependent inducer of cytochrome P450 3A4 (CYP3A4). As many ARVs are substrates and/or inhibitors or inducers of CYP3A4, there is concern about DDIs with dexamethasone either as a perpetrator or a victim. Assessment of DDIs that involve dexamethasone is complex as dexamethasone is used at a range of daily doses (generally 0.5 up to 40 mg) and a treatment course can be short, long, or intermittent. Moreover, DDIs with dexamethasone have been evaluated only for a limited number of drugs. Here, we summarize the available in vitro and in vivo data on the interaction potential of dexamethasone and provide recommendations for the management of DDIs with ARVs, considering various dexamethasone dosages and treatment durations.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Humans, HIV Infections, Dexamethasone, Pharmaceutical Preparations, Drug Interactions, Cytochrome P-450 CYP3A, SARS-CoV-2, COVID-19 Drug Treatment |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 27 May 2022 08:33 |
| Last Modified: | 15 Feb 2023 01:16 |
| DOI: | 10.1093/jac/dkab412 |
| Open Access URL: | https://doi.org/10.1093/jac/dkab412 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3155585 |
Dimensions
Dimensions
